Zimmer Biomet Holdings Inc (NYSE:ZBH) insider Didier Deltort sold 360 shares of Zimmer Biomet stock in a transaction on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the transaction, the insider now owns 1,194 shares of the company’s stock, valued at approximately $166,264.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Didier Deltort also recently made the following trade(s):
- On Monday, September 9th, Didier Deltort sold 84 shares of Zimmer Biomet stock. The stock was sold at an average price of $140.42, for a total value of $11,795.28.
ZBH traded up $1.44 during midday trading on Tuesday, hitting $138.52. 1,106,567 shares of the company traded hands, compared to its average volume of 1,222,623. The company’s 50-day moving average is $136.28 and its 200 day moving average is $125.26. The company has a quick ratio of 0.56, a current ratio of 1.19 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $28.69 billion, a PE ratio of 18.13, a price-to-earnings-growth ratio of 2.50 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 52 week low of $96.99 and a 52 week high of $140.71.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Friday, September 27th. Zimmer Biomet’s dividend payout ratio is currently 12.57%.
Several equities analysts have recently weighed in on the company. Cowen set a $140.00 price target on Zimmer Biomet and gave the company a “hold” rating in a report on Friday, July 26th. Oppenheimer upped their price target on shares of Zimmer Biomet from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, July 29th. ValuEngine downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. Argus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a research note on Monday, August 12th. Finally, Raymond James lifted their target price on shares of Zimmer Biomet from $145.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet presently has an average rating of “Buy” and a consensus price target of $142.26.
A number of large investors have recently bought and sold shares of the business. Personal Wealth Partners purchased a new position in Zimmer Biomet in the second quarter worth about $26,000. TRUE Private Wealth Advisors purchased a new stake in Zimmer Biomet during the second quarter valued at approximately $26,000. Coastal Investment Advisors Inc. raised its position in Zimmer Biomet by 271.0% in the second quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 187 shares during the period. Private Ocean LLC raised its position in Zimmer Biomet by 34.8% in the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 80 shares during the period. Finally, CSat Investment Advisory L.P. boosted its stake in shares of Zimmer Biomet by 240.0% during the 2nd quarter. CSat Investment Advisory L.P. now owns 323 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 228 shares during the last quarter. 89.39% of the stock is owned by institutional investors and hedge funds.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: What is a capital gain?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.